Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a
dismal prognosis, with only modest advances in therapeutic strategies over the past several …

Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest
human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises …

Purpose: Histologic transformation to small cell lung cancer (SCLC) is a mechanism of
treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma …

Small-cell lung cancer (SCLC) cases represent approximately 15% of all lung cancer cases,
remaining a recalcitrant malignancy with poor survival and few treatment options. In the last …

Small cell lung cancer (SCLC) is a devastating disease with high proliferative and metastatic
capacity. SCLC has been classified into molecular subtypes based on differential …

Small cell lung cancer (SCLC) is highly aggressive with poor prognosis. Despite a relative
prevalence of circulating tumour DNA (ctDNA) in SCLC, liquid biopsies are not currently …

Small cell lung cancer (SCLC) is a highly aggressive malignancy characterized by rapid
growth and early metastasis and is susceptible to treatment resistance and recurrence …

Treatments for cancer patients are becoming increasingly complex, and there is a growing
desire from clinicians and patients for biomarkers that can account for this complexity to …

Lung cancer (LuC) is one of the leading causes of death in the world, and due to the
complex mechanisms and widespread metastasis, diagnosis and treatment are challenging …

With the rapid development of science and technology, cell-free DNA (cfDNA) is rapidly
becoming an important biomarker for tumor diagnosis, monitoring and prognosis, and this …